CSF biomarkers for mild cognitive impairment

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · see citing works

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Observations on the brains of demented old people

Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · see citing works

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · see citing works

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,007 · see citing works

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity

Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,913 · see citing works

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease

Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., & Fahrenholz, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3922 · Cited by 1,132 · see citing works

Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor

Buxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., & Black, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27765 · Cited by 933 · see citing works

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing

Yu, G., Nishimura, M., Arawaka, S., Levitan, D. J., Zhang, L., Tandon, A., Song, Y., Rogaeva, E. A., Chen, F., Kawarai, T., et al. (2000) · Nature · doi:10.1038/35024009 · Cited by 906 · see citing works

Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1

Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866 · see citing works

Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide

Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 833 · see citing works

aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation

Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00189-2 · Cited by 805 · see citing works

tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?

Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

DeCarli, C. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00262-x · Cited by 569 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works

High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype

Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442 · see citing works

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works

Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias

Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W. C., Masliah, E., Terry, R. D., Hill, L. R., Lessin, P. J., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 407 · see citing works

APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos

Goutte, C., Tsunozaki, M., Hale, V. A., & Priess, J. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022523499 · Cited by 404 · see citing works

Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid

Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385 · see citing works

LONG-TERM FOLLOW-UP OF PATIENTS WHO RECEIVED 10,098 SPINAL ANESTHETICS

Vandam, L. D. (1956) · JAMA · doi:10.1001/jama.1956.02970070018005 · Cited by 382 · see citing works

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease

Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R. N., Simms, G., Beyreuther, K. T., & Masters, C. L. (1988) · Neurology · doi:10.1212/wnl.38.11.1688 · Cited by 369 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 339 · see citing works

Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

Wiltfang, J., Esselmann, H., Bibl, M., Av, S., Otto, M., Paul, S., Schmidt, B., Klafki, H., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 268 · see citing works

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease

Blennow, K., Vanmechelen, E., & Hampel, H. J. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 263 · see citing works

Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

Büerger, K., Teipel, S. J., Zinkowski, R. P., Blennow, K., Arai, H., Engel, R. R., Hofmann‐Kiefer, K., McCulloch, C., Ptok, U., Heun, R., et al. (2002) · Neurology · doi:10.1212/wnl.59.4.627 · Cited by 255 · see citing works

Both total and phosphorylated tau are increased in Alzheimer's disease

Sjögren, M. J. C. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 254 · see citing works

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238 · see citing works

CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

Sjögren, M. J. C., Minthon, L., Davidsson, P., Granérus, A., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 237 · see citing works

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N. C., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B. G., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 236 · see citing works

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke

Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., & Blennow, K. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-23-402 · Cited by 215 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 212 · see citing works

A critical discussion of the role of neuroimaging in mild cognitive impairment*

Wolf, H., Jelić, V., Gertz, H., Nordberg, A. K., Julin, P., & Wahlund, L. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.10.x · Cited by 211 · see citing works

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample

Andreasen, N. C., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B. G., & Blennow, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1488 · Cited by 210 · see citing works

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.

Nostrand, W. E. V., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M. B., Rozemüller, A. J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J. B., & Cotman, C. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2551 · Cited by 205 · see citing works

Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194 · see citing works

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients

Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180 · see citing works

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients

Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works

Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Otto, M., Esselmann, H., Schulz‐Schaeffer, W., Neumann, M., Schröter, A., Ratzka, P., Cepek, L., Zerr, I., Steinacker, P., Windl, O., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1099 · Cited by 170 · see citing works

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease

Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166 · see citing works

Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P., & Blennow, K. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.9.x · Cited by 160 · see citing works

Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies

Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 159 · see citing works

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

Galasko, D. R., Clark, C., Chang, L., Miller, B. L., Green, R. C., Motter, R. N., & Seubert, P. A. (1997) · Neurology · doi:10.1212/wnl.48.3.632 · Cited by 153 · see citing works

Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

Sjögren, M. J. C., Davidsson, P., Wallin, A., Granérus, A., Grundström, E., Askmark, H., Vanmechelen, E., & Blennow, K. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048642 · Cited by 145 · see citing works

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works

A Meta-Analysis of Structural and Functional Brain Imaging in Dementia of the Alzheimer's Type: A Neuroimaging Profile

Zakzanis, K. K., Graham, S. J., & Campbell, Z. (2003) · Neuropsychology Review · doi:10.1023/a:1022318921994 · Cited by 143 · see citing works

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies

Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141 · see citing works

Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 139 · see citing works

Low frequency of post-lumbar puncture headache in demented patients

Blennow, K., Wallin, A., & Häger, O. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04221.x · Cited by 130 · see citing works

Soluble Amyloid β-Protein Is a Marker of Alzheimer Amyloid in Brain But Not in Cerebrospinal Fluid

Tabaton, M., Nunzi, M. G., Xue, R., Usiak, M., AUTILIO‐GAMBETTI, L., & Gambetti, P. L. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1634 · Cited by 126 · see citing works

CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study

Arai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Morikawa, Y.-I., Horikawa, E., Kohno, H., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7501 · Cited by 125 · see citing works

Diagnostic accuracy of alzheimer’s disease: A neuropathological study

Kosunen, O., Soininen, H. S., Paljärvi, L., Heinonen, O., Talasniemi, S., & Riekkinen, P. J. (1996) · Acta Neuropathologica · doi:10.1007/s004010050412 · Cited by 121 · see citing works

The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process

Sjögren, M. J. C., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, Å., Vanmechelen, E., Wallin, A., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051268 · Cited by 116 · see citing works

Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients

Fukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., & Yanagisawa, K. (2000) · European Neurology · doi:10.1159/000008156 · Cited by 112 · see citing works

Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

Holmberg, B., Johnels, B., Blennow, K., & Rosengren, L. (2002) · Movement Disorders · doi:10.1002/mds.10321 · Cited by 104 · see citing works

Biochemical Evidence for the Long-Tail Form (Aβ1-42/43) of Amyloid β Protein as a Seed Molecule in Cerebral Deposits of Alzheimer′s Disease

Tamaoka, A., Kondo, T., Odaka, A., Sahara, N., Sawamura, N., Ozawa, K., Suzuki, N., Shoji, S., & Mori, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2740 · Cited by 101 · see citing works

The amyloid‐ β (A β ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A β peptide

Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., Maler, J. M., Rüther, E., Kornhuber, J., & Wiltfang, J. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1048 · Cited by 100 · see citing works

Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease

Maruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Higuchi, S., Matsushita, S., Yoshida, H., et al. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7814 · Cited by 97 · see citing works

Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF

Kahle, P. J., Jakowec, M. W., Teipel, S. J., Hampel, H. J., Petzinger, G. M., Monte, D. A. D., Silverberg, G. D., Möller, H. ‐., Yesavage, J. A., Tinklenberg, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.54.7.1498 · Cited by 93 · see citing works

Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Arai, H., DeBernardis, J. F., Kerkman, D. J., McCulloch, C., Padberg, F., Faltraco, F., Goernitz, A., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.376 · Cited by 92 · see citing works

Cerebrospinal protein tau is elevated in early Alzheimer's disease

Riemenschneider, M. J., Buch, K., Schmolke, M., Kurz, A., & Guder, W. G. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12810-x · Cited by 90 · see citing works

Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

Southwick, P. C., Yamagata, S. K., Echols, C. L., Higson, G. J., Neynaber, S. A., Parson, R. E., & Munroe, W. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010259.x · Cited by 89 · see citing works

Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid

Hesse, C., Larsson, H. E., Fredman, P., Minthon, L., Andreasen, N., Davidsson, P., & Blennow, K. (2000) · Neurochemical Research · doi:10.1023/a:1007516210548 · Cited by 89 · see citing works

Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF

Averback, P. (2000) · Neurology · doi:10.1212/wnl.55.7.1068 · Cited by 88 · see citing works

Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease

Kurz, A., Riemenschneider, M., Buch, K., Willoch, F., Bartenstein, P., Müller, U., & Guder, W. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00020 · Cited by 85 · see citing works

Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease

van Gool, W. A., Walstra, G. J. M., Bolhuis, P. A., Kuiper, M. A., & Wolters, E. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370221 · Cited by 82 · see citing works

Protein Analyses in Cerebrospinal Fluid

Blennow, K., Fredman, P., Wallin, A., Gottfries, C., Långström, G., & Svennerholm, L. T. (2008) · European Neurology · doi:10.1159/000116918 · Cited by 81 · see citing works

Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 70 · see citing works

Primary Degenerative Mild Cognitive Impairment: Study Population, Clinical, Brain Imaging and Biochemical Findings

Lautenschlager, N. T., Riemenschneider, M., Drzezga, A. E., & Kurz, A. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051284 · Cited by 67 · see citing works

Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

Jellinger, K. A. (1996) · Acta Neuropathologica · doi:10.1007/s004010050418 · Cited by 65 · see citing works

Clinical Heterogeneity of Probable Alzheimer's Disease

Blennow, K., & Wallin, A. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500208 · Cited by 60 · see citing works

Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach

Iqbal, K., del Alonso, A. C., Gondal, J. A., Gong, C., Haque, N., Khatoon, S., Sengupta, A., Wang, J.-Z., & Grundke, I. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_22 · Cited by 60 · see citing works

Severity of family distress of schizophrenia—fact or artifact?

Damodaran, S. S. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03443.x · Cited by 57 · see citing works

Low cerebrospinal-fluid concentrations of soluble amyloid $beta;-protein precursor in hereditary Alzheimer's disease

Farlow, M. R. (1992) · The Lancet · doi:10.1016/0140-6736(92)91771-y · Cited by 55 · see citing works

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.

Morikawa, Y., Arai, H., Matsushita, S., Kato, M., Higuchi, S., Miura, M., Kawakami, H., Higuchi, M., Okamura, N., Tashiro, M., et al. (1999) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04156.x · Cited by 49 · see citing works

Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid

Blennow, K., Wallin, A., Gottfries, C. G., Månsson, J., & Svennerholm, L. T. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260910 · Cited by 46 · see citing works

One-Carbon Metabolism and Other Biochemical Correlates of Cognitive Impairment as Visualized by Principal Component Analysis

Gottfries, J., Blennow, K., Lehmann, M., Regland, B., & Gottfries, C. G. (2001) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870101400302 · Cited by 36 · see citing works

Immunoglobulin M in Cerebrospinal Fluid: Reference Values Derived from 111 Healthy Individuals 18–88 Years of Age

Blennow, K., Skoog, I. G., Wallin, A., Wikkelsø, C., & Fredman, P. (2008) · European Neurology · doi:10.1159/000117248 · Cited by 32 · see citing works

Cerebrospinal Fluid ‘Neuronal Thread Protein’ Comes from Serum by Passage over the Blood-Brain Barrier

Blennow, K., Wallin, A., & Chong, J. K. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0023 · Cited by 21 · see citing works

Genetic testing for Alzheimerʼs disease: how close is reality?

Blennow, K., & Skoog, I. G. (1999) · Current Opinion in Psychiatry · doi:10.1097/00001504-199907000-00019 · Cited by 15 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

The Alzheimer's Disease Neuroimaging Initiative

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease

Portet, F. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.085332 · Cited by 652 · see citing works

Identifying and validating biomarkers for Alzheimer's disease

Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · see citing works

Mild cognitive impairment and its management in older people

Eshkoor, S. A., Mun, C. Y., Ng, C. K., & Hamid, T. A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s73922 · Cited by 428 · see citing works

Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300 · see citing works

Biomarkers: Mining the Biofluid Proteome

Veenstra, T. D., Conrads, T. P., Hood, B. L., Avellino, A. M., Ellenbogen, R. G., & Morrison, R. S. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500006-mcp200 · Cited by 244 · see citing works

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

Bryś, M., Pirraglia, E., Rich, K. E., Rolstad, S., Mosconi, L., Switalski, R., Głodzik-Sobańska, L., Santi, S. D., Zinkowski, R., Mehta, P. D., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.010 · Cited by 186 · see citing works

Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer's disease

Levey, A. I., Lah, J. J., Goldstein, F. C., Steenland, K., & Bliwise, D. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.006 · Cited by 180 · see citing works

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus

Ågren-Wilsson, A., Lekman, A. Y., Sjöberg, W., Rosengren, L., Blennow, K., Bergenheim, A. T., & Malm, J. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00890.x · Cited by 160 · see citing works

Clinical trials in mild cognitive impairment: lessons for the future

Jelić, V. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072926 · Cited by 155 · see citing works

Robust and Universal SERS Sensing Platform for Multiplexed Detection of Alzheimer’s Disease Core Biomarkers Using PAapt-AuNPs Conjugates

Zhang, X., Liu, S., Song, X., Wang, H., Wang, J., Wang, Y., Huang, J., & Yu, J. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00974 · Cited by 148 · see citing works

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 127 · see citing works

CSF biomarkers for Alzheimer's disease: current utility and potential future use

Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 124 · see citing works

Cerebral Hemodynamics in Mild Cognitive Impairment: A Systematic Review

Beishon, L., Haunton, V. J., Panerai, R. B., & Robinson, T. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170181 · Cited by 122 · see citing works

Circulating Biomarkers of Cognitive Decline and Dementia

Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120 · see citing works

Increased plasma levels of lipocalin 2 in mild cognitive impairment

Choi, J., Lee, H., & Suk, K. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.03.023 · Cited by 119 · see citing works

Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study

Nordlund, A., Rolstad, S., KLANG, O., Edman, Å., Hansen, S., & Wallin, A. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.171066 · Cited by 117 · see citing works

Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults

Stomrud, E., Hansson, O., Zetterberg, H., Blennow, K., Minthon, L., & Londos, E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.316 · Cited by 116 · see citing works

Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years

Stomrud, E., Hansson, O., Minthon, L., Blennow, K., Rosén, I., & Londos, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.025 · Cited by 114 · see citing works

Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip

Vestergaard, M. C. M., Kerman, K., Kim, D., Hiep, H. M., & Tamiya, E. (2007) · Talanta · doi:10.1016/j.talanta.2007.06.009 · Cited by 111 · see citing works

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment

Klavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., & Humpel, C. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.05.003 · Cited by 110 · see citing works

Introduction: Mild cognitive impairment: beyond controversies, towards a consensus

Winblad, B. G., Palmer, K., Kivipelto, M., Jelić, V., & Fratiglioni, L. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01382.x · Cited by 107 · see citing works

Biomarkers in Sporadic and Familial Alzheimer’s Disease

Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106 · see citing works

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Stomrud, E., Björkqvist, M., Janciauskiene, S. M., Minthon, L., & Hansson, O. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt44 · Cited by 105 · see citing works

Polymeric Complements to the Alzheimer's Disease Biomarker β-Amyloid Isoforms Aβ1–40 and Aβ1–42 for Blood Serum Analysis under Denaturing Conditions

Urraca, J. L., Aureliano, C. S. A., Schillinger, E., Esselmann, H., Wiltfang, J., & Sellergren, B. (2011) · Journal of the American Chemical Society · doi:10.1021/ja202908z · Cited by 101 · see citing works

Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99 · see citing works

Sphingomyelin SM(d18:1/18:0) is Significantly Enhanced in Cerebrospinal Fluid Samples Dichotomized by Pathological Amyloid-β 42 , Tau, and Phospho-Tau-181 Levels

Koal, T., Klavins, K., Seppi, D., Kemmler, G., & Humpel, C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142319 · Cited by 98 · see citing works

Candidate genes, pathways and mechanisms for alcoholism: an expanded convergent functional genomics approach

Rodd, Z. A., Bertsch, B. A., Strother, W. N., Le-Niculescu, H., Balaraman, Y., Hayden, E. P., Jerome, R. E., Lumeng, L., Nürnberger, J. I., Edenberg, H. J., et al. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500420 · Cited by 95 · see citing works

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

Mistur, R. L., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 94 · see citing works

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease

Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 92 · see citing works

A SERS-Based Sandwich Assay for Ultrasensitive and Selective Detection of Alzheimer’s Tau Protein

Zengi̇n, A., Tamer, U., & Çaykara, T. (2013) · Biomacromolecules · doi:10.1021/bm400968x · Cited by 94 · see citing works

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

Głodzik-Sobańska, L., Pirraglia, E., Bryś, M., Santi, S. D., Mosconi, L., Rich, K. E., Switalski, R., Louis, L. S., Sadowski, M. J., Martiniuk, F. T., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.019 · Cited by 90 · see citing works

Exploring Biomarkers for Alzheimer’s Disease

Sharma, N. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/18828.8166 · Cited by 86 · see citing works

Olfactory Dysfunction as a Global Biomarker for Sniffing out Alzheimer’s Disease: A Meta-Analysis

Kotecha, A., Corrêa, A., Fisher, K., & Rushworth, J. V. (2018) · Biosensors · doi:10.3390/bios8020041 · Cited by 82 · see citing works

Longitudinal CSF isoprostane and MRI atrophy in the progression to AD

de Leon, M. J., Mosconi, L., Li, J., Santi, S. D., Yao, Y., Tsui, W.-H., Pirraglia, E., Rich, K. E., Javier, E., Bryś, M., et al. (2007) · Journal of Neurology · doi:10.1007/s00415-007-0610-z · Cited by 82 · see citing works

Modified screen printed electrode for development of a highly sensitive label-free impedimetric immunosensor to detect amyloid beta peptides

Truong, L. T. N., Takamura, Y., Tamiya, E., & Vestergaard, M. C. M. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.08.036 · Cited by 79 · see citing works

Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells

Beier, H. T., Cowan, C. B., Chou, I.-H., Pallikal, J., Henry, J. E., Benford, M. E., Jackson, J. B., Good, T. A., & Coté, G. L. (2007) · Plasmonics · doi:10.1007/s11468-007-9027-x · Cited by 75 · see citing works

The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood

Hulme, C. H., Brown, S. J., Fuller, H. R., Riddell, J. S., Osman, A., Chowdhury, J., Kumar, N., Johnson, W. E. B., & Wright, K. T. (2016) · Spinal Cord · doi:10.1038/sc.2016.174 · Cited by 69 · see citing works

Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia

Pugliese, M., Carrasco, J. L., Andrade, C., Mas, E., Mascort, J., & Mahy, N. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.01.017 · Cited by 68 · see citing works

Biomarkers in translational research of Alzheimer’s Disease

Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67 · see citing works

Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease

Samakashvili, S., Ibáñez, C., Simó, C., Gil-Bea, F. J., Winblad, B. G., Cedazo-Mı́nguez, Á., & Cifuentes, A. (2011) · Electrophoresis · doi:10.1002/elps.201100139 · Cited by 69 · see citing works

Mild Cognitive Impairment and Dementia

Albert, M., & Blacker, D. (2006) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.144039 · Cited by 65 · see citing works

Increasing CSF phospho-tau levels during cognitive decline and progression to dementia

Andersson, C., Blennow, K., Almkvist, O., Andreasen, N., Engfeldt, P., Johansson, S., Lindau, M. P., & Eriksdotter, M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.027 · Cited by 65 · see citing works

Tauopathies: recent insights into old diseases.

Delacourte, A. (2005) · PubMed · Cited by 65 · see citing works

Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools

Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 64 · see citing works

Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease

Bryś, M., Glodzik, L., Mosconi, L., Switalski, R., Santi, S. D., Pirraglia, E., Rich, K. E., Kim, B. C., Mehta, P. D., Zinkowski, R., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0968 · Cited by 62 · see citing works

Synaptic vesicle cycle and amyloid β: Biting the hand that feeds

Ovsepian, S. V., O’Leary, V. B., Záborszky, L., Ntziachristos, V., & Dolly, J. O. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.01.011 · Cited by 56 · see citing works

CSF amyloid  38 as a novel diagnostic marker for dementia with Lewy bodies

Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199398 · Cited by 54 · see citing works

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI

Nordlund, A., Rolstad, S., KLANG, O., LIND, K., PEDERSEN, M., Blennow, K., Edman, Å., Hansen, S., & Wallin, A. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s135561770808079x · Cited by 53 · see citing works

Identification of Brain Cell Death Associated Proteins in Human Post-mortem Cerebrospinal Fluid

Burgess, J., Lescuyer, P., Hainard, A., Burkhard, P. R., Turck, N., Michel, P., Rossier, J. S., Reymond, F., Hochstrasser, D. F., & Sanchez, J. (2006) · Journal of Proteome Research · doi:10.1021/pr060160v · Cited by 54 · see citing works

Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression

Yang, H., Lyutvinskiy, Y., Herukka, S.-K., Soininen, H., Rutishauser, D., & Zubarev, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132102 · Cited by 52 · see citing works

The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes

Ritsner, M. S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9464-4 · Cited by 51 · see citing works

Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease

Humpel, C. (2011) · World Journal of Psychiatry · doi:10.5498/wjp.v1.i1.8 · Cited by 51 · see citing works

Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients

Zenzmaier, C., Marksteiner, J., Kiefer, A., Berger, P., & Humpel, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06158.x · Cited by 50 · see citing works

Predicting Alzheimer dementia in mild cognitive impairment patients

Borroni, B., Luca, M. D., & Padovani, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.023 · Cited by 51 · see citing works

Cerebrospinal Fluid Tau Cleaved by Caspase-6 Reflects Brain Levels and Cognition in Aging and Alzheimer Disease

Ramcharitar, J., Albrecht, S., Afonso, V. M., Kaushal, V., Bennett, D. A., & LeBlanc, A. C. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182a0a39f · Cited by 47 · see citing works

Impaired Peripheral Endothelial Microvascular Responsiveness in Alzheimer's Disease

Khalil, Z. G., LoGiudice, D., Khodr, B., Maruff, P. T., & Masters, C. L. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11106 · Cited by 47 · see citing works

Evaluation of spectral ratio measures from spontaneous MEG recordings in patients with Alzheimer's disease

Poza, J., Hornero, R., Abásolo, D., Fernández, A., & Mayo-Íscar, A. (2008) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2007.12.004 · Cited by 44 · see citing works

Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease

Inoue, K., Garner, C. O., Ackermann, B. L., Oe, T., & Blair, I. A. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2395 · Cited by 46 · see citing works

Neuropsychological profiles in MCI and in depression: Differential cognitive dysfunction patterns or similar final common pathway disorder?

Zihl, J., Reppermund, S., Thüm, S., & Unger, K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.12.002 · Cited by 41 · see citing works

Circulating Biomarker Panels in Alzheimer's Disease

Zafari, S., Backes, C., Meese, E. U., & Keller, A. (2015) · Gerontology · doi:10.1159/000375236 · Cited by 37 · see citing works

Impact Assessment of Neuroimaging

Hüsing, B., Jäncke, L., & Tag, B. (2006) · vdf Hochschulverlag AG an der ETH Zürich eBooks · doi:10.3218/3151-5 · Cited by 36 · see citing works

Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept

Rolstad, S., Nordlund, A., Eckerström, C., Gustavsson, M. H., Zetterberg, H., & Wallin, A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000203130 · Cited by 34 · see citing works

Next-generation biomarker discovery in Alzheimer’s disease using metabolomics–from animal to human studies

Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34 · see citing works

T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease

Haris, M., Yadav, S. K., Rizwan, A., Singh, A., Cai, K., Kaura, D., Wang, E., Davatzikos, C., Trojanowski, J. Q., Melhem, E. R., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.02.016 · Cited by 33 · see citing works

Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment

Eckerström, C., Andréasson, U., Olsson, E., Rolstad, S., Blennow, K., Zetterberg, H., Malmgren, H., Edman, Å., & Wallin, A. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000289814 · Cited by 32 · see citing works

Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, K., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091594 · Cited by 32 · see citing works

A SERS nanocellulose-paper-based analytical device for ultrasensitive detection of Alzheimer's disease

Yuan, W., Yuan, H., Li, R., Yong, R., Mitrović, I. Z., Lim, E. G., Duan, S., & Song, P. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342447 · Cited by 33 · see citing works

Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects

Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000330468 · Cited by 31 · see citing works

Prostaglandin D2 synthase and its post‐translational modifications in neurological disorders

Lescuyer, P., Gandini, A., Burkhard, P. R., Hochstrasser, D. F., & Sanchez, J. (2005) · Electrophoresis · doi:10.1002/elps.200500292 · Cited by 31 · see citing works

White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels

Grambaitė, R., Stenset, V. T. V., Reinvang, I., Walhovd, K. B., Fjell, A. M., & Fladby, T. (2009) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709990932 · Cited by 30 · see citing works

Contourlet-based hippocampal magnetic resonance imaging texture features for multivariant classification and prediction of Alzheimer’s disease

Gao, N., Tao, L., Huang, J., Zhang, F., Li, X., O’Sullivan, F., Chen, S., Tian, S.-J., Mahara, G., Luo, Y., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0296-1 · Cited by 30 · see citing works

High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment

Rolstad, S., Nordlund, A., Eckerström, C., Gustavsson, M. H., Blennow, K., Olesen, P. J., Zetterberg, H., & Wallin, A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091012 · Cited by 27 · see citing works

The Memory and Aging Telephone Screen: Development and preliminary validation

Rabin, L. A., Saykin, A. J., Wishart, H. A., Nutter‐Upham, K. E., Flashman, L. A., Paré, N., & Santulli, R. B. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.02.002 · Cited by 28 · see citing works

The search for antecedent biomarkers of Alzheimer's disease

Fagan, A. M., Csernansky, C. A., Morris, J. C., & Holtzman, D. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8404 · Cited by 29 · see citing works

Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory Impairment

Andersson, C., Blennow, K., Johansson, S., Almkvist, O., Engfeldt, P., Lindau, M. P., & Eriksdotter, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000097354 · Cited by 26 · see citing works

Analysis of Cerebrospinal Fluid of Alzheimer Patients

Marksteiner, J., Pirchl, M., Ullrich, C., OBERBAUER, H., Blasko, I., Lederer, W., Hinterhuber, H., & Humpel, C. (2008) · Pharmacology · doi:10.1159/000156487 · Cited by 26 · see citing works

Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there?

Monien, B. H., Apostolova, L. G., & Bitan, G. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1293 · Cited by 25 · see citing works

Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries

Xu, X., Kwon, J., Yan, R., Apio, C., Song, S. C., Heo, G., Yang, Q., Timsina, J., Liu, M., Budde, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0562 · Cited by 26 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Correlate With Electroencephalography Parameters Assessed by Exact Low-Resolution Electromagnetic Tomography (eLORETA)

Hata, M., Tanaka, T., Kazui, H., Ishii, R., Canuet, L., Pascual-Marqui, R. D., Aoki, Y., Ikeda, S., Sato, S., Suzuki, Y., et al. (2016) · Clinical EEG and Neuroscience · doi:10.1177/1550059416662119 · Cited by 24 · see citing works

Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly

Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 23 · see citing works

Plasma lipids metabolism in mild cognitive impairment and Alzheimer’s disease

Costa, A. C., Joaquim, H. P. G., Forlenza, O. V., Talib, L. L., & Gattaz, W. F. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1369566 · Cited by 23 · see citing works

Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study

Jonsson, M., Zetterberg, H., Rolstad, S., Edman, A., Gouw, A. A., Bjerke, M., Lind, K., Blennow, K., Pantoni, L., Inzitari, D., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000341576 · Cited by 22 · see citing works

Electroencephalography for Early Detection of Alzheimer’s Disease in Subjective Cognitive Decline

Shim, Y., Yang, D. W., Ho, S. H., Hong, Y. J., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., & Kang, S. W. (2022) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2022.21.4.126 · Cited by 20 · see citing works

Investigating the association between a history of depression and biomarkers of Alzheimer’s disease, cerebrovascular disease, and neurodegeneration in patients with dementia

Salwierz, P., Thapa, S., Taghdiri, F., Vasilevskaya, A., Anastassiadis, C., Tang‐Wai, D. F., Golas, A., & Tartaglia, M. C. (2023) · GeroScience · doi:10.1007/s11357-023-01030-x · Cited by 20 · see citing works

High Prevalence of Stress and Low Prevalence of Alzheimer Disease CSF Biomarkers in a Clinical Sample with Subjective Cognitive Impairment

Eckerström, M., Berg, A. I., Nordlund, A., Rolstad, S., Sacuiu, S. F., & Wallin, A. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000448326 · Cited by 19 · see citing works

Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay

Kravchenko, K., Kulawik, A., Hülsemann, M., Kühbach, K., Zafiu, C., Herrmann, Y., Linnartz, C., Peters, L., Bujnicki, T., Willbold, J., et al. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0153 · Cited by 19 · see citing works

Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer’s Disease Neuroimaging Initiative)

Harris, P., Suarez, M. F., Surace, E. I., Méndez, P. C., Martin, M. E., Clarens, M. F., Tapajóz, F., Campos, J., Sevlever, G. E., Allegri, R., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84292 · Cited by 18 · see citing works

The study of Alzheimer’s disease biomarkers

Vestergaard, M. C. M., Kerman, K., & Tamiya, E. (2006) · Nanobiotechnology · doi:10.1007/s12030-006-0002-y · Cited by 17 · see citing works

CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly

Stomrud, E., Forsberg, A., Hägerström, D., Ryding, E., Blennow, K., Zetterberg, H., Minthon, L., Hansson, O., & Londos, E. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338185 · Cited by 17 · see citing works

Association of cognitive impairment with plasma levels of folate, vitamin B12 and homocysteine in the elderly.

Dimopoulos, N. P., Piperi, C., Salonicioti, A., Psarra, V., Gazi, F., Nounopoulos, C., Lea, R. W., & Kalofoutis, A. (2006) · PubMed · Cited by 17 · see citing works

N-Glycomics of Cerebrospinal Fluid: Method Comparison

Cho, B. G., Reyes, C. D. G., & Mechref, Y. S. (2021) · Molecules · doi:10.3390/molecules26061712 · Cited by 16 · see citing works

Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden

Rolstad, S., Berg, A. I., Eckerström, C., Johansson, B. E. A., & Wallin, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142694 · Cited by 14 · see citing works

Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer’s Disease

Wang, B., Zhong, X., Fields, L. G., Lu, H., Zhu, Z., & Li, L. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00332 · Cited by 15 · see citing works

A novel monoclonal antibody specific for the amino-truncated β-amyloid Aβ5-40/42 produced from caspase-cleaved amyloid precursor protein

Murayama, K. S., Kametani, F., Tabira, T., & Araki, W. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.11.010 · Cited by 14 · see citing works

Censoring‐robust time‐dependent receiver operating characteristic curve estimators

Nuño, M. M., & Gillen, D. L. (2021) · Statistics in Medicine · doi:10.1002/sim.9216 · Cited by 13 · see citing works

Diagnostic methods and biomarkers for Alzheimer’s disease

Bagyinszky, E., Youn, Y. C., An, S. S. A., & Kim, S. (2014) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-014-0198-5 · Cited by 13 · see citing works

Is Olfactory Epithelium Biopsy Useful for Confirming Alzheimer’s Disease?

Godoy, M. D. C. L., Fornazieri, M. A., Doty, R. L., Pinna, F. D. R., Farfel, J. M., dos Santos, G. B., Molina, M., Ferretti‐Rebustini, R. E. D. L., Leite, R. E. P., Suemoto, C. K., et al. (2018) · Annals of Otology Rhinology & Laryngology · doi:10.1177/0003489418814865 · Cited by 13 · see citing works

Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer’s disease: a pilot study

Costa, A. C., Joaquim, H. P. G., Forlenza, O. V., Gattaz, W. F., & Talib, L. L. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01034-9 · Cited by 13 · see citing works

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease

Andreasen, N., & Blennow, K. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.10.011 · Cited by 192 · see citing works

CSF tau and β-amyloid as biomarkers for mild cognitive impairment

Hampel, H., & Blennow, K. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/hhampel · Cited by 52 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

Papaliagkas, V. T., Kalinderi, K., Vareltzis, P. K., Μoraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108976 · Cited by 73 · see citing works

Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P., & Blennow, K. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.9.x · Cited by 160 · see citing works